Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BiTE-EV in Relapsed/Refractory Acute B-Cell Lymphoblastic Leukemia
NCT06890494Phase 1Recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Lipid-based Nanoparticles, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BiTE-EV in Acute B-cell lymphoblastic leukemia (B-ALL), sponsored by Beijing Gaobo Hospital. Primary endpoints: Incidence of Treatment-Related Adverse Events at 3 months, Severity of Treatment-Related Adverse Events at 3 months and 2 more. Started Jan 2025; status: recruiting.
02
Drugs
BiTE-EV
03
Conditions
Acute B-cell lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06890494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06890494.